Tumour vasculature targeting agents in hybrid/conjugate drugs

Abstract

Tumour vasculature targeting has been a very active area of cancer drug discovery over the last decade. Growth of solid tumours beyond a certain point requires a sufficient blood supply in order for them to develop and metastasise. While novel anti-angiogenic and vascular disrupting agents represent an important contribution to the armoury of anti-cancer agents they nevertheless usually require combination with standard cytotoxic therapy in order to demonstrate positive clinical outcomes. In line with this consensus, a new concept has arisen, namely the design of functional hybrids where at least one component of the design targets a tumour angiogenic/vasculature pathway. This review will outline examples of such hybrid/conjugate-based approaches. Emphasis will be placed on their preclinical evaluation with particular focus on the RGD/NGR-conjugates, heparin-related hybrids and antibody-drug conjugates. In conclusion, the benefits and shortcomings of hybrids under development will be discussed in the context of future directions and applications.

A new target ligand Ser–Glu for PEPT1-overexpressing cancer imaging

“…[6][7][8] Although many ligands demonstrate highly specific targeting ability in vitro, only a small number of them practically enhance the tumor accumulation of systemically administered NPs. [9][10][11][12][13][14][15] This limitation has inspired attempts to develop ligands for tumor-targeted applications with high efficiency.…”

Anti-Tumor Effect of a Novel Soluble Recombinant Human Endostatin: Administered as a Single Agent or in Combination with Chemotherapy Agents in Mouse Tumor Models

“…Moreover, due to unstable genome, tumor cells frequently develop multi-drug resistance to various chemotherapies [56]. While Endostatin exerts a cytostatic effect on endothelium, which is less prone to the development of drug resistance [55], [57]. In the present study, we have demonstrated that a combination of conventional chemotherapy agent, CTX, with rhEndostatin exhibits an additive effect on the metastasis of B16 melanoma.…”

Steroid Conjugates as Potential Anti-Cancer Agents

“…Различным аспектам создания и применения гибридов и конъюгатов посвящены многочисленные обзоры [1][2][3][4][5][6][7][8][9][10]. Кроме того, опубликованы обзоры, посвященные новым направлениям, сформировавшимся недавно: синтезу полифункциональных биосовместимых наноматериалов, синтезу библиотек конъюгатов на основе определенных фармакофоров и направленных на определенные биомишени, созданию QSAR-моделей гибридов и конъюгатов [2,3,[11][12][13][14][15][16][17][18][19][20][21][22].…”